XERS - Xeris Biopharma Holdings, Inc. News

Leerink Partners Maintains Outperform on Xeris Biopharma Holdings, Raises Price Target to $16

Leerink Partners analyst Roanna Ruiz maintains Xeris Biopharma Holdings (NASDAQ:XERS) with a Outp

seekingalpha.com

Xeris Biopharma Holdings, Inc. (XERS) Discusses XP-8121 Program Overview, Phase 3 Study Details and

Xeris Hosts Webinar Detailing Its Comprehensive Development Program for XP-8121, an Investigational,

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to

Xeris Biopharma To Host XP‑8121 Program Overview Detailing Phase 3 Study And Commercial Opportunity;

Initiation of Phase 3 registrational study on track by year-end; topline results expected in late 20

Xeris Hosts Webinar Detailing Its Comprehensive Development Program for XP-8121, an Investigational,

CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceu

defenseworld.net

Connor Clark & Lunn Investment Management Ltd. Takes $1.01 Million Position in Xeris Biopharma Holdi

Connor Clark and Lunn Investment Management Ltd. bought a new position in shares of Xeris Biopharma

defenseworld.net

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Given Average Recommendation of “Hold” by Brokerages

Xeris Biopharma Holdings, Inc. (NASDAQ: XERS - Get Free Report) has received an average recommendati

Xeris Announces Details for XP-8121 Program Overview Webinar

CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceu

seekingalpha.com

Xeris Biopharma: A Commercial Stage Pharma That May Be A Slow-Burn Buy Opportunity

Xeris Biopharma Holdings, Inc. achieved record 2024 revenues of $203M, up 24%, with robust growth ac

Barclays Maintains Overweight on Xeris Biopharma Holdings, Raises Price Target to $12

Barclays analyst Glen Santangelo maintains Xeris Biopharma Holdings (NASDAQ:XERS) with a Overweig

marketbeat.com

Xeris Biopharma Q2 Earnings Call Highlights

Xeris Biopharma NASDAQ: XERS reported second-quarter total revenue of $92.1 million, up 29% from a y

seekingalpha.com

Xeris Biopharma Holdings, Inc. (XERS) Q2 2026 Earnings Call Transcript

zacks.com

Compared to Estimates, Xeris Biopharma (XERS) Q2 Earnings: A Look at Key Metrics

The headline numbers for Xeris Biopharma (XERS) give insight into how the company performed in the q

Xeris Biopharma Holdings Q2 EPS $(0.18) Misses $0.00 Estimate, Sales $92.100M Beat $90.225M Estimate

Xeris Biopharma Holdings (NASDAQ:XERS) reported quarterly losses of $(0.18) per share which missed t

Xeris Biopharma Holdings Raises FY2026 Sales Guidance from $380.000M-$390.000M to $385.000M-$390.000

Xeris Biopharma Holdings (NASDAQ:XERS) raises FY2026 sales outlook from $380.000 million-$390.000 mi

Xeris Biopharma Reports Second Quarter 2026 Financial Results

CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceu

Xeris Biopharma to Report Second Quarter 2026 Financial Results on August 6, 2026

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to

Xeris Biopharma to Report Second Quarter 2026 Financial Results on August 6, 2026

CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceu

zacks.com

Xeris Biopharma (XERS) Moves 6.8% Higher: Will This Strength Last?

Xeris Biopharma (XERS) was a big mover last session on higher-than-average trading volume. The lates

CORRECTING and REPLACING Xeris Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Please replace the release issued earlier today with the following corrected version that provides a

CORRECTING and REPLACING Xeris Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Please replace the release issued earlier today with the f

Xeris Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-grow

Xeris Announces Updates to Its Board of Directors

CHICAGO--(BUSINESS WIRE)--Xeris Announces Updates to Its Board of Directors.

Xeris Pharmaceuticals Issued Notice Of Allowance From U.S. Patent And Trademark Office Regarding Its

Xeris Pharmaceuticals, Inc., a wholly owned subsidiary of Biopharma Holdings, Inc. (NASDAQ:XERS), a

Xeris Biopharma Announces Notice of Allowance From U.S. Patent and Trademark Office for New Patent C

CHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc., a wholly owned subsidiary of Biopharma Holdin

Xeris Biopharma Announces Private Exchange of Convertible Notes

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to

Xeris Biopharma Enters Separate Exchange Agreements With Certain Holders Of Its 8.00% Convertible Se

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a fast-growing biopharmaceutical company committed to

Xeris Biopharma Holdings Raises FY2026 Sales Guidance from $375.000M-$390.000M to $380.000M-$390.000

Xeris Biopharma Holdings (NASDAQ:XERS) raises FY2026 sales outlook from $375.000 million-$390.000 mi

Xeris Biopharma Holdings Q1 EPS $0.01 Beats $(0.00) Estimate, Sales $83.127M Beat $79.992M Estimate

Xeris Biopharma Holdings (NASDAQ:XERS) reported quarterly earnings of $0.01 per share which beat the

HC Wainwright & Co. Reiterates Buy on Xeris Biopharma Holdings, Maintains $10 Price Target

HC Wainwright & Co. analyst Brandon Folkes reiterates Xeris Biopharma Holdings (NASDAQ:XERS)

Xeris Biopharma Holdings Q4 Earnings Assessment

Xeris Biopharma Holdings Sees FY2026 Sales $375.000M-$390.000M vs $368.100M Est

Xeris Biopharma Holdings (NASDAQ:XERS) sees FY2026 sales of $375.000 million-$390.000 million vs $36

Xeris Biopharma Holdings Q4 EPS $0.06 Beats $0.04 Estimate, Sales $85.807M Beat $82.340M Estimate

Xeris Biopharma Holdings (NASDAQ:XERS) reported quarterly earnings of $0.06 per share which beat the

Earnings Scheduled For March 2, 2026

Why Are Shares Of Xeris Biopharma Falling Friday?

Xeris Biopharma Holdings shares are falling Friday after the company announced a patent infringement

A Peek at Xeris Biopharma Holdings's Future Earnings

Xeris Biopharma's Subsidiaries, Xeris Pharmaceuticals And Strongbridge Dublin Limited, File Recorlev

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a fast-growing biopharmaceutical company committed to

HC Wainwright & Co. Reiterates Buy on Xeris Biopharma Holdings, Maintains $10 Price Target

HC Wainwright & Co. analyst Brandon Folkes reiterates Xeris Biopharma Holdings (NASDAQ:XERS)

Outlook Therapeutics, Intelligent Bio Solutions And Other Big Stocks Moving Lower In Friday's Pre-Ma

Barclays Initiates Coverage On Xeris Biopharma Holdings with Overweight Rating, Announces Price Targ

Barclays analyst Glen Santangelo initiates coverage on Xeris Biopharma Holdings (NASDAQ:XERS) wit

Xeris Biopharma Holdings Raises FY2025 Sales Guidance from $280.000M-$290.000M to $285.000M-$290.000

Xeris Biopharma Holdings (NASDAQ:XERS) raises FY2025 sales outlook from $280.000 million-$290.000 mi

Xeris Biopharma Holdings Q3 Sales $74.380M Beat $74.180M Estimate

Xeris Biopharma Holdings (NASDAQ:XERS) reported quarterly sales of $74.380 million which beat the an

Earnings Scheduled For November 6, 2025

American Regent And Xeris Pharmaceuticals Launch Gvoke VialDx, First Concentrated Liquid Glucagon Fo

First concentrated, ready-to-dilute liquid glucagon available for diagnostic proceduresSHIRLEY, N.Y.

HC Wainwright & Co. Assumes Xeris Biopharma Holdings at Buy, Announces Price Target of $10

HC Wainwright & Co. analyst Brandon Folkes assumes Xeris Biopharma Holdings (NASDAQ:XERS) wit

Earnings Scheduled For August 7, 2025

Oppenheimer Maintains Outperform on Xeris Biopharma Holdings, Raises Price Target to $7

Oppenheimer analyst Leland Gershell maintains Xeris Biopharma Holdings (NASDAQ:XERS) with a Outpe

Earnings Scheduled For May 8, 2025

Earnings Outlook For Xeris Biopharma Holdings